Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thykamine - Devonian

Next Previous
Drug Profile

Thykamine - Devonian

Alternative Names: PCT-233; PUR-0110; Thykamine™

Latest Information Update: 15 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PurGenesis Technologies
  • Developer Devonian
  • Class Anti-inflammatories; Antiacnes; Antifibrotics; Cardiovascular therapies; Hepatoprotectants; Radioprotectives; Skin disorder therapies
  • Mechanism of Action Antioxidants; Cytokine inhibitors; Interleukin 10 modulators; Reactive oxygen species inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Erythrodysaesthesia; Ulcerative colitis
  • Preclinical Fibrosis; Non-alcoholic steatohepatitis
  • Discontinued Acne; Cardiovascular disorders; Psoriasis

Most Recent Events

  • 21 Jul 2026 Health Canada approves CTA for Thykamine in Atopic Dermatitis (In Infants, In Children, In Adolescents)
  • 21 Jul 2026 Devonian plans a phase II/III trial in Atopic dermatitis (In Infants, In Children, In Adolescents) in Canada (Topical)
  • 19 Feb 2026 Pharmacodynamics data from a preclinical studies in Non-alcoholic steatohepatitis released by Devonian

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top